AXISS Axillary Survey Study

Dear clinical researcher,

As the presence of positive axillary lymph nodes is an important prognostic factor in breast cancer, the axillary lymph node dissection (ALND) was standard of care for ages. Two studies changed this understanding. The American College of Surgeons Oncology Group Z0011 trial revealed the safety of omitting axillary lymph node dissection (ALND) for women with fewer than three positive sentinel lymph nodes (SLNs) who are undergoing breast-conservation therapy (BCT), being followed by whole-breast radiation therapy (BCT) and systemic therapy (Giuliano AE, et al. Ann Surg.2010;252:426–32). Moreover, results of the EORTC 10981-22023 AMAROS showed that axillary lymph node dissection and axillary radiotherapy after a positive sentinel node provide comparable axillary control for patients with T1-2 primary breast cancer and no palpable lymphadenopathy (Donker et al. Lancet Oncol. 2014).
EURECCA Breast group would like to explore the consequences of these studies on your daily practice.
Therefore, we ask you to join our AXISS (Axillary Survey study) survey on the axillary treatment of positive SN breast cancer patients and  a bit later on the negative axilla.   
Please feel free to access the survey here.
If you are considering to join our survey, please fill it in and return this by email to
We look forward to a close collaboration with you and we are interested to receiving any feedback at your convenience.
Welcome on board!
Sabrina Maaskant and Marjut Leidenius
Principal Investigators
Nicole Verheuvel, PhD student
Petra Boelens
Riccardo Audisio
Cornelis van de Velde


ESSO Industry Partner